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background:  While studies have found high bleeding rates when patients require triple antithrombotic therapy (oral anticoagulant, ADP receptor 
inhibitor and aspirin), there is limited information on the relative bleeding risks of clopidogrel vs. prasugrel in these regimens.
methods: We evaluated acute myocardial infarction (AMI) patients treated with percutaneous coronary intervention (PCI) at 233 hospitals in the 
TRANSLATE-ACS observational study from 4/2010-10/2012. GUSTO-defined bleeding at 6 months in patients discharged on aspirin+anticoagulant+
clopidogrel (triple-C), aspirin+anticoagulant+prasugrel (triple-P), aspirin+clopidogrel (dual-C), and aspirin+prasugrel (dual-P) were compared using 
inverse probability weighted propensity adjusted Cox modeling.
results: Of 11,757 patients, 526 (4.5%) were discharged on triple-C, 91 (0.8%) on triple-P. 7,715 (66%) on dual-C, and 3,425 (29%) on dual-P. 
Compared with patients on dual antiplatelet therapy, those treated with triple therapy had significantly higher bleeding risk regardless of ADP 
receptor inhibitor selected (Figure). Patients treated with triple-P had similar bleeding risks as those receiving triple-C (6.6% vs. 8.8%, adjusted HR 
of 0.54, 95% CI 0.17-1.74).
Conclusion: In the TRANSLATE-ACS observational study, while AMI patients on triple therapy had a higher risk of bleeding relative to those on dual 
therapy, the relative increase in bleeding risk with triple therapy was similar for prasugrel and clopidogrel.
 
